Biovica International has signed a Master Service Agreement and the initial Work Order with a US-based biopharmaceutical company specializing in breast cancer. The agreement enables Biovica to provide TKa testing services to support the development of new therapeutic treatments through pre-clinical and clinical studies. Under the agreement, Biovica will contribute to the development of first-in-class macromolecule inhibitor therapeutics for breast cancer, particularly for patients who no longer respond to CDK4/6 inhibitors.

The services will utilize Biovica's TKa assay and expertise in interpreting TKa measurement dynamics. The initial TKa work order is valued at SEK 0.75M.